TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23414496

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 189
Study: 21415383

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 4360

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 4360

Group type: COMPARATOR
Intervention: glyburide
Number of subjects: 4360
Study: 19752472

Group type: COMPARATOR
Intervention: CAMI+ (computer-assisted motivational intervention plus enhanced home visit)
Number of subjects: 235

Group type: COMPARATOR
Intervention: CAMI-only (computer-assisted motivational intervention only)
Number of subjects: 235

Group type: COMPARATOR
Intervention: CAMI+
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: CAMI-only
Number of subjects: 235
Study: 16942833

Group type: EXPERIMENTAL
Intervention: Duloxetine and rehabilitation (group A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rehabilitation alone (group B)
Number of subjects: 112
Study: 15067266

Group type: EXPERIMENTAL
Intervention: Extrusion group (n = 21)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Derotation group (n = 28)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 91
Study: 11464356

Group type: COMPARATOR
Intervention: Local anesthetic alone (40 mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local anesthetic plus buprenorphine (0.3 mg)
Number of subjects: 40
Study: 9713726

Group type: EXPERIMENTAL
Intervention: Crystalloid plus PFC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Crystalloid alone
Number of subjects: 10
Study: 7809537

Group type: EXPERIMENTAL
Intervention: Itraconazole (6 mg/kg/day for 120 days)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Allopurinol (8.5 mg/kg/day for 60 days)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo (for 60 days)
Number of subjects: 202
Study: 3422261

Group type: EXPERIMENTAL
Intervention: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG) for 6 cycles
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG)
Number of subjects: 187
Study: 358140

Group type: EXPERIMENTAL
Intervention: dihydroergotoxine
Number of subjects: 34
Study: 30797045

Group type: EXPERIMENTAL
Intervention: Humanitarian intervention targeting stress-alleviation
Number of subjects: 817
Study: 30794976

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Number of subjects: 0
Study: 28007348

Group type: EXPERIMENTAL
Intervention: Bihormonal bionic pancreas
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care (conventional or sensor-augmented insulin pump therapy)
Number of subjects: 43
Study: 24938396

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no PRP injections)
Number of subjects: 16
Study: 23456672

Group type: EXPERIMENTAL
Intervention: IM clodronate 100 mg twice weekly (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IM clodronate 100 mg once weekly (Group A)
Number of subjects: 60
Study: 22331940

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide plus rituximab (FCR)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Low MRD levels
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Intermediate MRD levels
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: High MRD levels
Number of subjects: 493
Study: 20163263

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium patch
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17367356

Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency (CRI)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Non-chronic renal insufficiency (non-CRI)
Number of subjects: 336
Study: 16301721

Group type: EXPERIMENTAL
Intervention: 500 mL of water ingestion before ultrasonographic examination (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No water ingestion at least 4 hours before the procedure (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 500 mL of water ingestion (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No water ingestion (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 150
Study: 12070447

Group type: EXPERIMENTAL
Intervention: CT-angiography
Number of subjects: 196
Study: 9793190

Group type: EXPERIMENTAL
Intervention: GnRH analog plus oral contraceptive (OC) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral contraceptive (OC) therapy alone
Number of subjects: 30
Study: 7657122

Group type: EXPERIMENTAL
Intervention: Tamoxifen, 20 mg/day per os (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen (group A)
Number of subjects: 120
Study: 2568711

Group type: EXPERIMENTAL
Intervention: alpha-agonist
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pharmacological treatment
Number of subjects: 44
Study: 364917

Group type: EXPERIMENTAL
Intervention: PGE2 gel (1 mg in viscous gel)
Number of subjects: 61
Study: 31926951

Group type: EXPERIMENTAL
Intervention: Early screening (14‐20 weeks)
Number of subjects: 962

Group type: COMPARATOR
Intervention: Routine screening (24‐28 weeks)
Number of subjects: 962
Study: 31279865

Group type: EXPERIMENTAL
Intervention: Aloysia polystachya powdered leaves (300 mg, twice a day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 54
Study: 25363466

Group type: EXPERIMENTAL
Intervention: 1-week DAFNE course
Number of subjects: 213

Group type: COMPARATOR
Intervention: 5-week DAFNE course
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Patients with baseline HbA1c ≥ 58 mmol/mol (≥ 7.5%)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both course formats
Number of subjects: 213
Study: 23942532

Group type: EXPERIMENTAL
Intervention: Peer-group-derived benchmarks (PGD-training)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Self-controlled basic VR training (SC-training)
Number of subjects: 68
Study: 21991734

Group type: EXPERIMENTAL
Intervention: CVC placement with ultrasound guidance
Number of subjects: 325

Group type: COMPARATOR
Intervention: CVC placement without ultrasound guidance
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Experienced ultrasound practitioners
Number of subjects: 325

Group type: COMPARATOR
Intervention: Non-experienced ultrasound practitioners
Number of subjects: 325
Study: 19627288

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 1520

Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 1520
Study: 16460294

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg for infants under 12 months, 40 mg for older children)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU for infants under 12 months, 100,000 IU for older children)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Zinc + Vitamin A supplementation
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (no supplementation)
Number of subjects: 187
Study: 15148064

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (in persons with diabetes)
Number of subjects: 132
Study: 10648454

Group type: EXPERIMENTAL
Intervention: Mesalamine (4 g daily for 18 months)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Mesalamine (4 g daily for 18 months) in isolated small bowel disease subgroup
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo in isolated small bowel disease subgroup
Number of subjects: 318
Study: 9308977

Group type: EXPERIMENTAL
Intervention: High-dose pyridoxine (30 or 50 mg/kg/day) by intravenous infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no pyridoxine)
Number of subjects: 90
Study: 8315942

Group type: EXPERIMENTAL
Intervention: Dialysis with new CU membrane
Number of subjects: 8
Study: 3548301

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem, 120 to 180 mg twice daily
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 to 50 mg twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg/day
Number of subjects: 207
Study: 30342255

Group type: EXPERIMENTAL
Intervention: SNAPSHOT intervention (9-month program including four home visits, 14 kid groups, and five parent groups)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Newsletter program (monthly mailings and family-focused healthy lifestyle information)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: SNAPSHOT intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Newsletter program
Number of subjects: 132
Study: 26464170

Group type: EXPERIMENTAL
Intervention: Primary HSCT (group A; N=166 patients)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Best available drug treatment (group B; N=261 patients)
Number of subjects: 669
Study: 24951633

Group type: EXPERIMENTAL
Intervention: Availability, Current issues and Anticipation training programme
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 145
Study: 22197071

Group type: COMPARATOR
Intervention: C1-inhibitor concentrate (C1-INH)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: C1-inhibitor concentrate (C1-INH-NF)
Number of subjects: 13
Study: 21153932

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music through headphones for one hour after surgery)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 70
Study: 18764771

Group type: EXPERIMENTAL
Intervention: ETR (400 mg or 800 mg twice daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: ETR (800 mg or 1200 mg twice daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: ETR
Number of subjects: 240
Study: 16269047

Group type: EXPERIMENTAL
Intervention: Enhanced immunosuppression with basiliximab
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group with triple-therapy (azathioprine, methylprednisolone, cyclosporine)
Number of subjects: 59
Study: 12006915

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (surgical intervention)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Intervention group (partial ileal bypass)
Number of subjects: 789
Study: 10188004

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: TENS in early stage AD
Number of subjects: 16
Study: 7759705

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg body weight over 15 min)
Number of subjects: 12
Study: 2405793

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (25.5 Gy in five to seven days)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Postoperative irradiation (60 Gy in a total of 8 weeks)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 471

Group type: COMPARATOR
Intervention: Postoperative irradiation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 471
Study: 7011354

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined infusion of aminophylline and salbutamol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 21
Study: 31797848

Group type: EXPERIMENTAL
Intervention: Punica granatum
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Terminalia chebula
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vitis vinifera
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 29061624

Group type: EXPERIMENTAL
Intervention: video+prompt card
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: decision aids+training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: video+prompt card and decision aids+training
Number of subjects: 0

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 0
Study: 26324395

Group type: EXPERIMENTAL
Intervention: Family/friend recommendations for mammograms within the last year
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Perceived mammography norms
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Support
Number of subjects: 539
Study: 23399956

Group type: EXPERIMENTAL
Intervention: Highest neighborhood socioeconomic status (nSES) quintile
Number of subjects: 74179

Group type: EXPERIMENTAL
Intervention: Ever-smoking rates
Number of subjects: 74179
Study: 21953682

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 20
Study: 19452376

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15994253

Group type: EXPERIMENTAL
Intervention: 5 mg nebulised salbutamol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study: 14521803

Group type: EXPERIMENTAL
Intervention: Single-agent paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum/paclitaxel-based chemotherapy
Number of subjects: 0
Study: 10228090

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 110
Study: 8686816

Group type: EXPERIMENTAL
Intervention: Total intravenous propofol anaesthesia (median total dose of propofol 710 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combined isoflurane anaesthesia (median end-expiratory concentration of isoflurane 0.45 vol %)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total intravenous propofol anaesthesia
Number of subjects: 20
Study: 1839799

Group type: EXPERIMENTAL
Intervention: Concomitant antibiotic‐anti‐inflammatory therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 40
Study: 6633131

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: No specific treatment (Control)
Number of subjects: 79
Study: 30550775

Group type: EXPERIMENTAL
Intervention: Sustainability via Active Garden Education (SAGE) intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SAGE intervention
Number of subjects: 20
Study: 28537652

Group type: EXPERIMENTAL
Intervention: VLCKD1 (50% protein intake replaced with synthetic amino acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VLCKD2 (placebo)
Number of subjects: 0
Study: 26814618

Group type: EXPERIMENTAL
Intervention: Reduced-intensity chemotherapeutic regimen
Number of subjects: 61
Study: 25007361

Group type: EXPERIMENTAL
Intervention: ABT 50 mg
Number of subjects: 775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study: 22687392

Group type: EXPERIMENTAL
Intervention: modafinil 200 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 19735903

Group type: EXPERIMENTAL
Intervention: Opioid rotation using equianalgesic dose tables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Starting dose of new opioid based on relative potency
Number of subjects: 0
Study: 17623486

Group type: EXPERIMENTAL
Intervention: Milk supplemented with 3 g CLA (cis-9, trans-11 and trans-10, cis-12)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15886218

Group type: EXPERIMENTAL
Intervention: Octreotide (300 microg b.i.d.) added to diuretics (furosemide and spironolactone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Discontinuation of diuretics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diuretics (furosemide and spironolactone)
Number of subjects: 20
Study: 11952509

Group type: EXPERIMENTAL
Intervention: Plasmacure PS06/Evaflux Eval 5A (Kuraray)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plasmaflo OP05W/Cascadeflo AC1770 (Asahi)
Number of subjects: 4
Study: 9797095

Group type: EXPERIMENTAL
Intervention: Endocrine evaluation between days 2 and 5 of a spontaneous menstrual cycle
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endocrine evaluation between days 22 and 25 of a spontaneous menstrual cycle
Number of subjects: 48
Study: 8587482

Group type: EXPERIMENTAL
Intervention: Albuterol (16 mg.d‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Albuterol with resistance exercise
Number of subjects: 22
Study: 2676872

Group type: EXPERIMENTAL
Intervention: Bunazosin (1 to 3 mg t.i.d.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propranolol (10 to 40 mg t.i.d.)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bunazosin and Propranolol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bunazosin vs Propranolol
Number of subjects: 48
Study: 367426

Group type: EXPERIMENTAL
Intervention: extra‐amniotic prostaglandin E2 gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: oral prostaglandin E2
Number of subjects: 60

Group type: COMPARATOR
Intervention: intravaginal prostaglandin E2
Number of subjects: 60

Group type: COMPARATOR
Intervention: intravenous oxytocin
Number of subjects: 60
Study: 31655422

Group type: EXPERIMENTAL
Intervention: Aquatic exercise + Far Infrared (FIR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 28550827

Group type: COMPARATOR
Intervention: Triple therapy (pantoprazol, amoxicillin, and clarithromycin 12/12 hours for 14 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1-5, and clarithromycin plus metronidazol 12/12 hours during days 6-10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tobacco consumption
Number of subjects: 60
Study: 26111333

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (oral amoxicillin 50 mg/kg/day for 5 days)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 23221573

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXCO) - 20.6 g ALA/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: High-oleic acid canola oil (HOCO) - 2.4 g ALA/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Western diet (WD) - 1.3 g ALA/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 36
Study: 20666881

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: GP use of CRP point of care test
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: GP communication skills training
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: GP use of both CRP tests and communication skills training
Number of subjects: 431
Study: 19796303

Group type: EXPERIMENTAL
Intervention: 25% H(2)O(2) gel with light enhancement
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 25% H(2)O(2) gel alone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Light alone with no peroxide
Number of subjects: 33
Study: 16414461

Group type: EXPERIMENTAL
Intervention: Augmented subscapularis transposition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Subscapularis transposition alone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intact rotator cuffs
Number of subjects: 61
Study: 14703424

Group type: EXPERIMENTAL
Intervention: 20 mg tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg tramadol plus 0.1 mg droperidol
Number of subjects: 60
Study: 10797611

Group type: EXPERIMENTAL
Intervention: Fluvastatin for 16 weeks
Number of subjects: 55
Study: 8866385

Group type: EXPERIMENTAL
Intervention: Cuff around the finger
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cuff around the wrist
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cuff around the large arm
Number of subjects: 55
Study: 1290441

Group type: EXPERIMENTAL
Intervention: Paracervical block using 20 ml of 1% lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uterosacral block using 2 ml of 2% lignocaine
Number of subjects: 0
Study: 6421138

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (IC STK)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intracoronary nitroglycerin (IC NTG)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Subtotal occlusion patients
Number of subjects: 55
Study: 31722585

Group type: EXPERIMENTAL
Intervention: Harmony® prenatal Test
Number of subjects: 6510

Group type: COMPARATOR
Intervention: HB‐cfDNA test
Number of subjects: 6510
Study: 29920941

Group type: EXPERIMENTAL
Intervention: Warm hand bath at 40°C for 10 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: No hand bath
Number of subjects: 40
Study: 30357270

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 776

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 776
Study: 27028981

Group type: EXPERIMENTAL
Intervention: Betahistine (48 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24766999

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22235353

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) in co-infected children with O. viverrini
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) in co-infected children with O. viverrini
Number of subjects: 200
Study: 19515110

Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole 15 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (conventional therapies)
Number of subjects: 100